Actavis to market, distribute authorized generic version of Valeant drug; Valeant to co-promote Actavis drug
PARSIPPANY, N.J. — Actavis will market and distribute an authorized generic version of a genital herpes ointment made by Valeant Pharmaceuticals International, the companies said Friday.
The agreement centers around Zovirax, known generically as acyclovir, in the 5% strength. The Food and Drug Administration approved the generic version, made by Mylan, on Wednesday. Financial terms of the deal were not disclosed.
Unlike an FDA-approved generic, an authorized generic is the branded drug marketed under its generic name at a discounted price, usually through a third-party company.
The agreement also gives Valeant the right to co-promote Actavis Specialty Brands’ Cordran Tape (flurandrenolide), a treatment for skin conditions like psoriasis, eczema and contact dermatitis, in the United States.
Novo Nordisk launches Race with Insulin contest with Charlie Kimball as spokesman
BIRMINGHAM, Ala. — Novo Nordisk has launched a diabetes awareness sweepstakes in which the winners get a free trip to the 2013 IndyCar finale, the Danish drug maker said Friday.
The company announced that it had hired IZOD IndyCar Series Charlie Kimball as spokesman for its Race with Insulin contest. Kimball, the first licensed driver with diabetes to race at the highest level of the series, was diagnosed with the disease during a routine doctor visit in 2007 while racing in Europe and is a user of Novo Nordisk’s NovoLog (insulin aspart [rDNA origin]).
"It takes an entire crew to help me manage both my car and my diabetes, so we can compete at the highest levels," Kimball said. "This program is a great way for people to show support, especially for friends and family affected by diabetes, and encourage them to share my story."
Contestants can take part through Sept. 15 by sharing Kimball’s story about the importance of team support with two or more friends or family. Registration is at a website created by the drug maker.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Covis buys rights to five drugs from Sanofi
ZUG, Switzerland — Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said Thursday.
The drug maker said it would buy full commercial rights to the prostate cancer drug Nilandron (nilutamide); the antimalarial, lupus and arthritis drug Plaquenil (hydroxychloroquine); Rilutek (riluzole), used to treat amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease; the enlarged prostate drug Uroxatral (alfuzosin hydrochloride); and the high-potassium drug Kayexalate (sodium polystyrene sulfate), under an agreement with Sanofi subsidiary Sanofi-Aventis U.S. Financial terms of the deal were not disclosed, but the drugs had sales of $114.6 million in 2012, Covis said.
"We are very pleased to announce the addition of these products to our existing portfolio," Covis CEO Jack Davis said. "Covis will continue to supply consistent, top-quality branded drugs, ensuring that patients receive the therapeutic care they need."